FLOT2 and metabolic dysfunction-associated steatohepatitis: Given that endocytosis of flotillin-1 and flotillin-2 is regulated by Fyn kinase [87] its pharmacological inhibition may proof to be beneficial in treating progressive disease and particularly NASH.